Nov 22, 2019
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
Nov 17, 2019
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
|
|
Nov 12, 2019
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
|
|
Nov 07, 2019
Esperion to Participate in Upcoming Investor Conferences
|
|
Nov 06, 2019
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
|
|
Nov 04, 2019
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
|
|
Oct 29, 2019
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
|
|
Oct 25, 2019
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
|
|
Sep 05, 2019
Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid
|
|
Aug 30, 2019
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|